(Reuters) -Shares of Gilead rose 3% after the U.S. Supreme Court on Friday upheld a federal mandate that requires health ...

Shares of Gilead Sciences Inc. GILD rose 1.60% to $107.62 Thursday, on what proved to be an all-around great trading session ...

Gilead Sciences has entered into an option and license deal with Kymera Therapeutics to support the development and sales of ...

Gilead Sciences (NASDAQ:GILD) and Kymera Therapeutics (NASDAQ:KYMR) announced an exclusive partnership on Wednesday to ...

Big Pharma delivers another life-saving medical advance, and another demonstration of the folly of price controls.

Kymera Therapeutics, Inc.'s stock rose on KT-621 data, but Sanofi's exit casts doubts. A Gilead Sciences, Inc. deal offers ...

Gilead Sciences, Inc. (NASDAQ: GILD) and Kymera Therapeutics, Inc. (NASDAQ: KYMR), today announced that they have entered ...

Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...

Under terms of the deal, Kymera will lead early research on novel oral CDK2 degraders for solid tumors, with Gilead assuming ...

Kymera Therapeutics is celebrating the signing of two partnerships, with Gilead Sciences taking an option on one molecular ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

The launch of the injection faces potential threats, including the Trump administration’s proposed cuts to federal funding ...